This revealed a statistically significant positive association between DNMT3A mutations and surface CD25 expression as well as a significant negative association in which patients with mutations in RUNX1 tended to have less CD33 on AML blasts (Fig. 2b). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.